Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 234,800 shares, a decline of 8.0% from the August 15th total of 255,200 shares. Approximately 6.3% of the shares of the company are short sold. Based on an average daily trading volume, of 36,400 shares, the short-interest ratio is currently 6.5 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a research report on Thursday, August 22nd.
Check Out Our Latest Analysis on Precision BioSciences
Precision BioSciences Stock Down 6.1 %
Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $3.46 EPS for the quarter, topping the consensus estimate of ($0.77) by $4.23. The firm had revenue of $49.90 million for the quarter, compared to analysts’ expectations of $8.50 million. Precision BioSciences had a negative return on equity of 7.64% and a net margin of 19.36%. During the same quarter in the previous year, the company earned ($3.00) earnings per share. On average, equities research analysts predict that Precision BioSciences will post 0.82 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC purchased a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned about 8.29% of Precision BioSciences at the end of the most recent quarter. Institutional investors own 37.99% of the company’s stock.
Precision BioSciences Company Profile
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Featured Stories
- Five stocks we like better than Precision BioSciences
- How Investors Can Find the Best Cheap Dividend Stocks
- This Is the Top Large-Cap Stock Insiders Are Buying
- Why is the Ex-Dividend Date Significant to Investors?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- 3 Best Fintech Stocks for a Portfolio Boost
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.